Company Overview
Bluejay Diagnostics, Inc. operates within the healthcare sector, specifically functioning as a medical diagnostics company that develops and offers the Symphony technology platform. This platform comprises an analyzer paired with single-use protein detection cartridges engineered to measure key diagnostic biomarkers present in blood samples. The company maintains a very small operational scale, employing only six individuals to support its current business activities. With a market capitalization of $2.03M and reported revenue figures classified as unavailable, the company's valuation indicates a micro-cap status typical of early-stage medical device firms. The minimal employee count relative to the specialized nature of medical diagnostics suggests a lean organizational structure focused on high-intensity development or niche market penetration rather than mass manufacturing. The absence of disclosed revenue data alongside the micro-cap designation implies that the firm is likely in a phase where product commercialization or market expansion is prioritized over established cash generation.
Financial Health
The company reports a net income of $-6,848,483 and an EBITDA of $-6,842,535 over the trailing twelve months, while revenue figures are not disclosed. The substantial disparity between the reported net income loss and the EBITDA figure reveals a significant cost structure burden, primarily driven by non-operating expenses or interest costs that erode earnings despite operational performance. Free cash flow stands at $-3,706,221, indicating that the company is burning cash at a rate that exceeds its operational cash generation, which severely limits its current financial flexibility and liquidity runway. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a valuation characteristic that typically signifies either a lack of recognized sales revenue or extreme cost inefficiencies preventing margin realization. The balance sheet presents a mixed picture with $5.16M in cash holdings against $129,558 in debt, resulting in a debt-to-equity ratio of 2.17. Despite the low absolute debt level, the elevated debt-to-equity ratio suggests a leveraged capital structure relative to the company's equity base, yet the substantial cash reserve provides a buffer against short-term solvency risks. The current ratio is reported at 4.88, which indicates a highly liquid position capable of covering short-term obligations more than four times over. However, return on equity is negative at -117.0% and return on assets is negative at -62.8%, metrics that reveal management has not yet achieved profitability or effective capital allocation to generate returns on the invested shareholder and asset bases.
Valuation Assessment
Valuation multiples for Bluejay Diagnostics, Inc. reflect its pre-profitability status, with a trailing P/E ratio listed as unavailable due to the lack of earnings. The forward P/E ratio is reported at -6.13, a negative multiple that implies the market is pricing in a future earnings trajectory that remains negative or that current earnings are not yet reflective of future operations. The price-to-book ratio stands at 0.20, indicating that the market values the company at only 20% of its book value, suggesting a deep discount to the assets recorded on the balance sheet rather than a market premium. Alternative valuation metrics such as the price-to-sales ratio are unavailable, while the EV/EBITDA stands at 0.46, a figure that is exceptionally low and often seen in distressed or high-growth pre-revenue companies where enterprise value is calculated differently than standard multiples. The stock has exhibited extreme volatility, trading between a 52-week low of $1.70 and a 52-week high of $40.80. Without a specific current price provided in the facts, the valuation context suggests the stock has experienced a massive contraction from its recent highs, trading significantly below the 52-week high of $40.80. The beta value is 0.72, indicating that the stock's price volatility is lower than the broader market, moving at roughly 28% less intensity than the S&P 500 during periods of market fluctuation.
Growth & Income
Growth metrics for Bluejay Diagnostics, Inc. show revenue growth year-over-year as unavailable, with earnings growth year-over-year also listed as unavailable. The inability to calculate a growth rate between revenue and earnings implies that the company has not yet generated sufficient revenue to sustain positive earnings growth or to establish a comparable baseline for future expansion. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available capital, including cash reserves, into growth initiatives such as research and development or operational scaling rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of historical financial performance data, preventing any definitive statement on whether earnings are growing faster or slower than revenue, while the absence of dividend income positions the stock strictly as a speculative growth play dependent on future commercialization of its medical diagnostics platform.